Simris Alg AB (publ) (ST:SIMRIS-B) — Market Cap & Net Worth
Market Cap & Net Worth: Simris Alg AB (publ) (SIMRIS-B)
Simris Alg AB (publ) (ST:SIMRIS-B) has a market capitalization of $8.14 Million (Skr75.62 Million) as of May 3, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #27351 globally and #605 in its home market, demonstrating a 0.45% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Simris Alg AB (publ)'s stock price Skr0.09 by its total outstanding shares 842104898 (842.10 Million). Analyse Simris Alg AB (publ) (SIMRIS-B) cash conversion ratio to see how efficiently the company converts income to cash.
Simris Alg AB (publ) Market Cap History: 2016 to 2026
Simris Alg AB (publ)'s market capitalization history from 2016 to 2026. Data shows change from $917.48 Million to $8.14 Million (-36.43% CAGR).
Index Memberships
Simris Alg AB (publ) is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
First North Sweden PI
FNSESEKPI
|
$14.99 Billion | 0.05% | #174 of 281 |
Weight: Simris Alg AB (publ)'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Simris Alg AB (publ) Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Simris Alg AB (publ)'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.40x
Simris Alg AB (publ)'s market cap is 2.40 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $917.48 Million | $726.23K | -$19.35 Million | 1263.35x | N/A |
| 2017 | $542.15 Million | $851.63K | -$22.98 Million | 636.60x | N/A |
| 2018 | $297.78 Million | $761.81K | -$23.97 Million | 390.88x | N/A |
| 2019 | $195.40 Million | $1.74 Million | -$26.91 Million | 112.11x | N/A |
| 2020 | $89.54 Million | $2.17 Million | -$25.60 Million | 41.34x | N/A |
| 2021 | $67.06 Million | $6.14 Million | -$28.36 Million | 10.93x | N/A |
| 2022 | $22.79 Million | $4.08 Million | -$24.42 Million | 5.59x | N/A |
| 2023 | $20.39 Million | $4.35 Million | -$37.30 Million | 4.68x | N/A |
| 2024 | $6.91 Million | $2.89 Million | -$34.60 Million | 2.39x | N/A |
| 2025 | $3.88 Million | $1.61 Million | -$26.81 Million | 2.40x | N/A |
Competitor Companies of SIMRIS-B by Market Capitalization
Companies near Simris Alg AB (publ) in the global market cap rankings as of May 3, 2026.
Key companies related to Simris Alg AB (publ) by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Simris Alg AB (publ) Historical Marketcap From 2016 to 2026
Between 2016 and today, Simris Alg AB (publ)'s market cap moved from $917.48 Million to $ 8.14 Million, with a yearly change of -36.43%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr8.14 Million | +109.81% |
| 2025 | Skr3.88 Million | -43.83% |
| 2024 | Skr6.91 Million | -66.13% |
| 2023 | Skr20.39 Million | -10.54% |
| 2022 | Skr22.79 Million | -66.01% |
| 2021 | Skr67.06 Million | -25.10% |
| 2020 | Skr89.54 Million | -54.18% |
| 2019 | Skr195.40 Million | -34.38% |
| 2018 | Skr297.78 Million | -45.07% |
| 2017 | Skr542.15 Million | -40.91% |
| 2016 | Skr917.48 Million | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Simris Alg AB (publ) was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $8.14 Million USD |
| MoneyControl | $8.14 Million USD |
| MarketWatch | $8.14 Million USD |
| marketcap.company | $8.14 Million USD |
| Reuters | $8.14 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Simris Alg AB (publ)
Simris Group AB (PUBL), a biotechnology company, develops, manufactures, and sells bioactive substances from microalgae in Sweden and internationally. It offers skincare products and pharmaceuticals; food ingredients; and Algae Omega-3, an omega-3 EPA and DHA line under the SIMRIS brand name. The company was incorporated in 2011 and is headquartered in Hammenhög, Sweden.